Drug
Nirmatrelvir clinical trials
Also written PF-07321332.
- studies test it
- 28
- open now
- 3
- in phase 3
- 6
- first study started
- 2016
Keep track of what changes. Save the nirmatrelvir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
28 studies that test it; most in 2022 (13)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2020 | 1 |
| 2021 | 12 |
| 2022 | 13 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 16
- Phase 2
- 9
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 11
Who runs them
Industry 23 · Other 5
Pfizer (22) · University of Melbourne (1) · Stanford University (1) · Harlan M Krumholz (1) · Genuine Research Center, Egypt (1) · University of Oxford (1) · UMC Utrecht (1)
Often tested with
Tested in the same studies.
Ritonavir (20) · Remdesivir (3) · Nirmatrelvir and ritonavir drug combination (2) · Hydroxychloroquine (2) · Ivermectin (2) · Nafamostat (1) · Enoxaparin (1) · Dalteparin (1)
Studies
Open first, then newest update. How each study uses nirmatrelvir is read from its arms, and is right about nine times in ten.
Testing it · 28
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)RecruitingPhase 2University of OxfordNCT05041907Written as Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)
- EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe DiseaseRecruitingPhase 3PfizerNCT05261139Written as nirmatrelvir
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingPhase 3UMC UtrechtNCT02735707Written as Nirmatrelvir/ritonavir + remdesivir
- A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19TerminatedPhase 1PfizerNCT05386472Written as nirmatrelvir
- A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating WomenCompletedPhase 1PfizerNCT05441215Written as nirmatrelvir
- Paxlovid for Treatment of Long CovidCompletedPhase 2Stanford UniversityNCT05576662Written as Nirmatrelvir
- EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19CompletedPhase 2/3PfizerNCT04960202Written as PF-07321332
- Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet FormulationCompletedPhase 1PfizerNCT05263895Written as PF-07321332/ritonavir
- A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.CompletedPhase 2Harlan M KrumholzNCT05668091Written as Nirmatrelvir
- STUDY OF PF-07321332 IN HEALTHY PARTICIPANTSCompletedPhase 1PfizerNCT04756531Written as PF-07321332 Dose 1
- A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.CompletedPhase 1PfizerNCT05339334Written as PF-07321332/ritonavir
- A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/RitonavirCompletedPhase 2PfizerNCT05567952Written as nirmatrelvir
- A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune SystemCompletedPhase 2PfizerNCT05438602Written as Nirmatrelvir
- A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney DiseaseTerminatedPhase 1PfizerNCT05487040Written as PF-07321332 (nirmatrelvir)/ritonavir
- Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy ParticipantsCompletedPhase 1PfizerNCT05263921Written as PF-07321332/ritonavir
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform TrialActive, not recruitingPhase 3University of MelbourneNCT04483960Written as Nirmatrelvir-Ritonavir
- PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy ParticipantsCompletedPhase 1PfizerNCT05064800Written as PF-07321332/ritonavir + Dabigatran
- Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With RitonavirCompletedPhase 1PfizerNCT04962230Written as PF-07321332/ritonavir
- Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult ParticipantsCompletedPhase 1PfizerNCT05129475Written as PF-07321332/ritonavir
- Drug-Drug Interaction Study to Estimate the Effect of PF-07321332/Ritonavir and Ritonavir on Midazolam in Healthy ParticipantsCompletedPhase 1PfizerNCT05032950Written as PF-07321332/ritonavir + Midazolam
See all 28 studies that test nirmatrelvir →
As the comparator · 1 — what is tested is compared with nirmatrelvir
Codes
What other systems call nirmatrelvir · ClinicalTrials.gg INT001662
- MeSH (NLM) C000718217nirmatrelvirConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7R9A5P7H32NIRMATRELVIRConfirmed FDA, NLM, Wikidata
- RxNorm 2587892One source FDA
- Wikidata Q106405348nirmatrelvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C182119NirmatrelvirOne source FDA
- DrugBank DB16691One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718217 | nirmatrelvir | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7R9A5P7H32 | NIRMATRELVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2587892 | — | One source FDA |
| Wikidata | Q106405348 | nirmatrelvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C182119 | Nirmatrelvir | One source FDA |
| DrugBank | DB16691 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.